A phase 1 dose escalation and expansion study of ZG006, a trispecific T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with refractory small cell lung cancer or neuroendocrine carcinoma.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Zhengzhou University, Henan Cancer Hospital, Sichuan University, West China Hospital of Sichuan University, Fujian Provincial Cancer Hospital, First Hospital of China Medical University, China Medical University, Jilin University, Zhejiang Cancer Hospital, First Affiliated Hospital of Xi'an Jiaotong University, Suzhou Zelgen Biopharmaceuticals Co., Ltd. (China)
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410823234